deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 4-arm NCT03040973

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial.

Sponsor: Novartis Pharmaceuticals

Conditions Advanced Solid Tumors Which Are cMET-dependent
Interventions Capmatinib Gefitinib Nazartinib Osimertinib
Updated 35 times since 2017 Last updated: Jan 30, 2026 Started: Aug 23, 2017 Primary completion: Jul 30, 2027 Completion: Jul 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03040973, this PHASE2 trial focuses on Advanced Solid Tumors Which Are cMET-dependent and remains ongoing. Sponsored by Novartis Pharmaceuticals, it has been updated 35 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Sep 2017 · 5 months · monthly snapshot~Sep 2017 – ~May 2018 · 8 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Dec 2023 · 6 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Feb 2025 · 2 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

35 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  4. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  5. Jun 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

▶ Show 30 earlier versions

  1. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  2. Mar 2025 — May 2025 [monthly]

    Recruiting PHASE2

  3. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

  4. Dec 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

  5. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  6. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  7. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  8. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  9. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  10. Dec 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  11. Jun 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  12. Feb 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  13. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  14. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  15. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  16. Mar 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  17. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  18. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  19. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  20. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  21. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  22. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  23. Sep 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting · Phase: PHASE4 → PHASE2

  24. Feb 2019 — Sep 2019 [monthly]

    Recruiting PHASE4

  25. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE4

  26. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE4

  27. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  28. Sep 2017 — May 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  29. Apr 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE4

  30. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Cologne, Germany , Copenhagen, Denmark , Dijon, France , Edmonton, Canada , Hanover, Germany , Kunming, China , Leuven, Belgium , Madrid, Spain , Milan, Italy and 4 more locations